Copenhaver, Philip F
- Oregon Health & Science University · Anatomy & Cell Biology (NIH department code)
From the FY2022 NIH awards this investigator leads as contact PI. The department is the award's.
FY2022 NIH rank #13,616
- Long-Funded
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2006 through FY2022Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2022 award categories
- Anatomy & Cell Biology
NIH Funding · FY2022
Linked Award Amount
$766.9K
Full award amounts, FY2022
Award Records
1
Records listing this PI
Award-Linked Rank
#13,616
By linked amount among FY2022 PIs
Earliest Year Loaded
2006
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2022 award records by amount
NIH award records listing Copenhaver, Philip F as a PI. Multi-PI records show the full award amount for context.
- 1R56AG078220-01R56Contact PITherapeutic targeting a membrane estrogen receptor with a novel non-steroidal compound for Alzheimer's diseaseOregon Health & Science University · Anatomy & Cell Biology (NIH department code)$766.9Kaward amount
Award organization
Organizations that administered FY2022 awards listing Copenhaver, Philip F as a PI.
FY2022 award administered by Oregon Health & Science University (OR).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2006First NIH AwardOregon Health & Science University
- 2007$500K Cumulative Funding
- 2009$1M Cumulative Funding
- 2012$2M Cumulative Funding
- 2020Entered Top 50% NationallyRanked #876
- 2020Entered Top 25% NationallyRanked #876
- 2020Entered Top 10% NationallyRanked #876
- 2020Entered Top 5% NationallyRanked #876
- 2022$5M Cumulative Funding